Patents Issued in November 6, 2003
  • N-substituted indole-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action
    Publication number: 20030207892
    Abstract: The invention relates to novel N-substituted indole-3-glyoxylamides, to processes for their preparation and to their pharmaceutical use. The compounds have antiasthmatic, antiallergic and immuno-suppressant/immunomodulating actions.
    Type: Application
    Filed: April 1, 2003
    Publication date: November 6, 2003
    Inventors: Guillaume Lebaut, Cecilia Menciu, Bernhard Kutscher, Peter Emig, Stefan Szelenyi, Kay Brune
  • Heterocyclic compounds
    Publication number: 20030207893
    Abstract: Heterocyclic compounds and methods of making them and using them.
    Type: Application
    Filed: March 8, 2002
    Publication date: November 6, 2003
    Inventors: Nicholas I. Carruthers, Wenying Chai, Curt A. Dvorak, James P. Edwards, Cheryl A. Grice, Jill A. Jablonowski, Lars Karlsson, Haripada Khatuya, Jennifer D. Kreisberg, Annette K. Kwok, Timothy W. Lovenberg, Kiev S. Ly, Barbara Pio, Chandravadan R. Shah, Siquan Sun, Robin L. Thurmond, Jianmei Wei, Wei Xiao
  • 1,4-Disubstituted benzenes as insecticides
    Publication number: 20030207894
    Abstract: Compounds of formula I: 1
    Type: Application
    Filed: January 29, 2003
    Publication date: November 6, 2003
    Inventors: George Theodoridis, Edward Barron, Daniel H. Cohen, Ellen M. Crawford, Thomas G. Cullen, Hongyan Qi, Elizabeth Rowley, Syed F. Ali, Walter H. Yeager, Christina B. Duggan
  • Tissue factor antagonists and methods of use thereof
    Publication number: 20030207895
    Abstract: The invention includes pharmaceutically active compounds and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for treating or prophylaxis of undesired thrombosis.
    Type: Application
    Filed: May 23, 2003
    Publication date: November 6, 2003
    Applicant: Sunol Molecular Corporation
    Inventors: Jin-An Jiao, Lawrence K. Luepschen, Esperanza L. Nieves, Hing C. Wong, Dean P. Taylor
  • Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts
    Publication number: 20030207896
    Abstract: The invention is directed to an imidazole derivative represented by formula (1): 1
    Type: Application
    Filed: November 5, 2002
    Publication date: November 6, 2003
    Inventors: Fujiko Konno, Yoshihiro Nagao, Kazuo Isomae, Mari Ohtsuka, Yoshiyuki Takahashi, Fumio Ishii, Hiroyuki Hirota, Sunao Takeda, Noriyuki Kawamoto, Haruyoshi Honda, Susumu Sato
  • Selective inhibitors of cyclooxygenase-2
    Publication number: 20030207897
    Abstract: The present invention relates to cyclooxygenase-2 (COX-2) selective inhibitors of formula I: 1
    Type: Application
    Filed: April 16, 2003
    Publication date: November 6, 2003
    Applicant: Pfizer Inc.
    Inventors: Kristin Lundy DeMello, Brian S. Bronk, Rhonda Marie Crosson
  • Aromatic thioether liver X-receptor modulators
    Publication number: 20030207898
    Abstract: The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula I.
    Type: Application
    Filed: December 23, 2002
    Publication date: November 6, 2003
    Applicant: Pharmacia Corporation
    Inventors: Nizal S. Chandrakumar, Christopher R. Dalton, James W. Malecha, Michael B. Tollefson, Jennifer Ann Van Camp, Philip B. Cox
  • Heterocyclylaminomethyloxazo-lidinones as antibacterials
    Publication number: 20030207899
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: March 6, 2003
    Publication date: November 6, 2003
    Applicant: AstraZeneca AB
    Inventor: Michael Barry Gravestock
  • Bicyclic pyridine and pyrimidine p38 kinase inhibitors
    Publication number: 20030207900
    Abstract: The present invention discloses compounds corresponding to formula 1
    Type: Application
    Filed: March 6, 2003
    Publication date: November 6, 2003
    Inventors: Jian Jeffrey Chen, Nolan James Dewdney, Christoph Martin Stahl
  • Hydroxyl-containing compounds
    Publication number: 20030207901
    Abstract: Disclosed are therapeutic compounds having the formula:
    Type: Application
    Filed: May 14, 2003
    Publication date: November 6, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson, Stephen J. Klaus, Anil M. Kumar, John Tulinsky
  • Heterocyclic compounds useful as inhibitors of tyrosine kinases
    Publication number: 20030207902
    Abstract: Disclosed are novel compounds of formula (I): 1
    Type: Application
    Filed: October 15, 2002
    Publication date: November 6, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Roger John Snow, Donghong A. Gao, Daniel R. Goldberg, Abdelhakim Hammach, Daniel Kuzmich, Tina Marie Morwick, Neil Moss, Anthony S. Prokopowicz, Robert D. Selliah, Hidenori Takahashi
  • 1,2,3,6-tetrahydropyrimidine-2-one compositions and therapeutic methods therewith for sexual disfunction
    Publication number: 20030207903
    Abstract: A therapeutic composition is provided that comprises a 1-R1-phenyl, 4-R2-phenyl substituted 1,2,3,6-tetrahydropyrimidine-2-one sensory nerve receptor agonist in a therapeutically effective amount. The sensory nerve receptor agonist may be represented by the general formula 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one wherein: R1 is -hydroxy, -chloro, - fluoro, -alkyl, -acetoxy, -trifluoromethyl ; and R2 is -nitro, -chloro, -fluoro, -alkyl, -trifluoromethyl. Therapeutic compositions of the invention elicit soothing, cooling, and stimulatory effects when formulated for topical delivery to human sexual organs and to anorectal areas of the body and are useful to alleviate dysfunction in sexual response and intercourse for both men and women.
    Type: Application
    Filed: July 8, 2002
    Publication date: November 6, 2003
    Inventor: Edward T. Wei
  • 1,2,3,6-tetrahydropyrimidine-2-one compositions and therapeutic methods therewith for pain and inflammation
    Publication number: 20030207904
    Abstract: A therapeutic composition is provided that comprises a 1-R1-phenyl, 4-R2-phenyl substituted 1,2,3,6-tetrahydropyrimidine-2-one sensory nerve receptor agonist in a therapeutically effective amount. The sensory nerve receptor agonist may be represented by the general formula 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one wherein: R1 is -hydroxy, -chloro, -fluoro, -alkyl, -acetoxy, -trifluoromethyl; and R2 is -nitro, -chloro, -fluoro, -alkyl, -trifluoromethyl. Therapeutic compositions of the invention reduce pain, itch, and a sense of discomfort, when formulated for topical delivery to the human lips, mouth, and to the anorectal area.
    Type: Application
    Filed: August 29, 2002
    Publication date: November 6, 2003
    Inventor: Edward T. Wei
  • Method of treating pain using nalbuphine and opioid antagonists
    Publication number: 20030207905
    Abstract: Inflammatory or neuropathic pain in both men and women patients is treated by administering, sequentially or simultaneously, (a) nalbuphine and (b) an opioid antagonist selected from naloxone, naltrexone and nalmefene, or a salt or prodrug of nalbuphine and/or the opioid antagonist. Preferably, administration is made of (a) an amount of from about 3 to about 8 mg nalbuphine and (b) from about 0.2 to about 0.8 mg of an opioid antagonist selected from naloxone, naltrexone and nalmefene, or a salt and/or prodrug of either (in an amount that produces in a patient the same blood concentration of the compound in question as would administration of said amount of the nalbuphine or opioid antagonist itself).
    Type: Application
    Filed: June 9, 2003
    Publication date: November 6, 2003
    Applicant: The Regents of the University of California
    Inventor: Jon D. Levine
  • Chemical compounds
    Publication number: 20030207906
    Abstract: Compounds of the general structural formula and use of the compounds and salts and solvates thereof, as therapeutic agents.
    Type: Application
    Filed: February 28, 2003
    Publication date: November 6, 2003
    Inventors: Mark W. Orme, Jason Scott Sawyer, Alain Claude-Marie Daugan, Francoise Gellibert, Romain Luc Marie Gosmini
  • Delivery of microparticle-conjugated drugs for inhibition of stenosis
    Publication number: 20030207907
    Abstract: Administration of a formulation comprising a antirestenotic compound conjugated to a microparticle carrier is effective to inhibit stenosis formation in a blood vessel. Such stenosis typically results, in the absence of treatment, from trauma to a vessel, such as an incision, excessive pressure, or an angioplasty procedure. The antirestenotic compound is typically an antiproliferative, immunosuppressive, or antiinflammatory drug, such as rapamycin, tacrolimus, paclitaxel, dexamethasone, or an active analog or derivative, or combinations thereof. The microparticle carrier comprises a suspension of gas-filled microbubbles or biocompatible polymeric microparticles, in a pharmaceutically acceptable liquid vehicle, and is effective to deliver the conjugated therapeutic to the site of vessel injury.
    Type: Application
    Filed: May 3, 2002
    Publication date: November 6, 2003
    Inventors: Patrick L. Iversen, Nicholas Kipshidze
  • Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment
    Publication number: 20030207908
    Abstract: The present invention relates to optically pure S-(−)-benzoquinolizlne carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof, substantially free of their R-(+)-isomers, to processes for preparation of the optically pure S-(−)-benzoquinoluzie carboylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof substantlly free of their R-(+)-isomers, and to pharmaceutical compositions comprising the S(+)-benzoquinolizie carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof.
    Type: Application
    Filed: May 8, 2000
    Publication date: November 6, 2003
    Inventors: Mahesh Vithalbhai Patel, Shivkumar Agarwal, Sreenivas Kandepu, Nitin Shetty, Dilip Jatashankar Upadhyay, Nishith Chandra Chaturvedi, Abraham Thomas, Noel John De Souza, Habil Fakhruddin Khorakiwala
  • Therapeutic acridone and acridine compounds
    Publication number: 20030207909
    Abstract: The present invention pertains to acridone and acridine compounds of formula (I), wherein either: (a) K is ═O, L is —H, alpha is a single bond, beta is a double bond, gamma is a single bond (acridones); or, (b) K is a 9-substituent, L is absent, alpha is a double bond, beta is a single bond, gamma is a double bond (acridines); and wherein: J1 is a 2- or 3-substituent; J2 is a 6- or 7-substituent; J1 and J2 are each independently a group of the formula —NHCO(CH2)nNR1R2, wherein: n is an integer from 1 to 5; and, R1 and R2 are independently hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, or R1 and R2, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 3 to 8 ring atoms; and wherein, when K is a 9-substituent.
    Type: Application
    Filed: April 4, 2003
    Publication date: November 6, 2003
    Inventors: Stephen Neidle, Richard John Harrison, Llyod Royston Kelland, Sharon Michele Gowan, Martin Anthony Read, Anthony Reszka
  • Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
    Publication number: 20030207910
    Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
    Type: Application
    Filed: August 7, 2002
    Publication date: November 6, 2003
    Inventors: Tao Wang, Zhongxing Zhang, Nicholas A. Meanwell, John F. Kadow, Zhiwei Yin, Qiufen May Xue
  • Substituted triazolopyridine compounds
    Publication number: 20030207911
    Abstract: A compound of formula 1
    Type: Application
    Filed: October 7, 2002
    Publication date: November 6, 2003
    Inventors: Matthias Heinrich Nettekoven, Sebastien Schmitt
  • Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
    Publication number: 20030207912
    Abstract: A compound of formula 1 1
    Type: Application
    Filed: January 16, 2003
    Publication date: November 6, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH. Co. KG
    Inventors: Christian Eickmeier, Sabine Germeyer, Matthias Grauert, Sabine Pestel, Michael P. Pieper, Georg Speck, Steffen Breitfelder
  • Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
    Publication number: 20030207913
    Abstract: The invention provides compounds of Formula I:
    Type: Application
    Filed: November 6, 2002
    Publication date: November 6, 2003
    Inventors: David W. Piotrowski, Jason K. Myers, Bruce N. Rogers, Eric Jon Jacobsen, Alice L. Bodnar, Vincent E. Groppi, Daniel Patrick Walker, Brad A. Acker
  • INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS
    Publication number: 20030207914
    Abstract: This invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.
    Type: Application
    Filed: April 19, 2002
    Publication date: November 6, 2003
    Applicant: BAYER CORPORATION
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Robert N. Sibley, Holia Hatoum-Mokdad, Mary-Katherine Monahan, David E. Gunn, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood
  • Compounds that modulate PPAR activity and methods of preparation
    Publication number: 20030207915
    Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
    Type: Application
    Filed: December 19, 2002
    Publication date: November 6, 2003
    Inventors: Xue-Min Cheng, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi
  • Compounds that modulate PPAR activity and methods of preparation
    Publication number: 20030207916
    Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
    Type: Application
    Filed: December 19, 2002
    Publication date: November 6, 2003
    Inventors: Xue-Min Cheng, Noe Erasga, Gary Frederick Filzen, Andrew Geyer, Chitase Lee, Bharat Kalidas Trivedi
  • Muscarinic antagonists
    Publication number: 20030207917
    Abstract: The present invention discloses compounds, which are novel muscarinic receptor antagonists, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such muscarinic receptor antagonists as well as methods for using them to treat cognitive disorders such as Alzheimer's disease.
    Type: Application
    Filed: October 8, 2002
    Publication date: November 6, 2003
    Applicant: Schering Corporation
    Inventors: Yuguang Wang, Samuel Chackalamannil
  • Method for inhibiting platelet aggregation
    Publication number: 20030207918
    Abstract: A method for inhibiting platelet aggregation in a patient in need thereof, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of between about 25 &mgr;g/kg, and 2) administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of the active drug, in an amount of about 0.15 &mgr;g/kg/min, wherein the active drug is tirofiban or a salt thereof.
    Type: Application
    Filed: May 1, 2003
    Publication date: November 6, 2003
    Inventors: Peter M. DiBattiste, David Schneider
  • Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
    Publication number: 20030207919
    Abstract: The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The present invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory drugs; treating and/or preventing gastrointestinal disorders; treating inflammatory disease states and disorders; and treating and/or preventing ophthalmic diseases or disorders.
    Type: Application
    Filed: May 8, 2003
    Publication date: November 6, 2003
    Inventors: Upul K. Bandarage, Qing Dong, Xinqin Fang, David S. Garvey, Gregory J. Mercer, Stewart K. Richardson, Joseph D. Schroeder, Tiansheng Wang
  • N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants
    Publication number: 20030207920
    Abstract: Compounds of formula [I] 1
    Type: Application
    Filed: September 12, 2002
    Publication date: November 6, 2003
    Inventors: Jean-Michel Altenburger, Gerard Cremer, Gilbert Lassalle, Mostafa Matrougui
  • Aromatic and heterocyclic thiazolyl thiourea compounds and use
    Publication number: 20030207921
    Abstract: Novel aromatic and heterocyclic thiazolyl thiourea compounds, pharameutical compositions including such, and methods for their use are disclosed. The compounds are effective agents for the treatment of HIV infection, including non-nucleoside inhibitor-resistant, and multi-drug resistant strains of HIV.
    Type: Application
    Filed: April 15, 2003
    Publication date: November 6, 2003
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Taracad K. Venkatachalam
  • Enzyme inhibitors
    Publication number: 20030207922
    Abstract: Diketoacids of Formula A are useful as inhibitors of viral polymerases.
    Type: Application
    Filed: September 10, 2002
    Publication date: November 6, 2003
    Applicant: Istituto Di Ricerche Di Biologia Molecolare P Angeletti SPA
    Inventors: Philippe Jean Sigfried Neuner, Vincenzo Summa
  • 2,'3-Amino-4-(n-hydroxyamino)-succinylamino-acetamides for use as cd23 formation inhibitors
    Publication number: 20030207923
    Abstract: Compounds of formula (I): wherein X1 is alkyl, sulphonyl or carboxy: X2 is hydrogen or alkyl; R1 is arylmethyl or heterocyclylmethyl; R2 is alkyl, alkenyl, aryl, cycloalkyl or cycloalkenyl; and R3 is hydrogen, alkyl, alkenyl, alkynyl or aryl; are useful in the treatment of disorders mediated by s-CD23.
    Type: Application
    Filed: May 14, 2003
    Publication date: November 6, 2003
    Inventors: Andrew Faller, Anne-Geraldine Rousseau, David Timothy Macpherson, Peter Henry Milner
  • Compounds that modulate PPAR activity and methods of preparation
    Publication number: 20030207924
    Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses methods for making the disclosed compounds.
    Type: Application
    Filed: December 20, 2002
    Publication date: November 6, 2003
    Inventors: Xue-Min Cheng, Noe Erasga, Gary Frederick Filzen, Andrew Geyer, Chitase Lee, Bharat Kalidas Trivedi
  • Methods of treatment with selective EP4 receptor agonists
    Publication number: 20030207925
    Abstract: The present invention provides a method of treating hypertension, liver failure, loss of patency of ductus arteriosus, glaucoma or ocular hypertension in a patient, comprising administering to the patient a therapeutically effective amount of a selective EP4 receptor agonist of Formula I 1
    Type: Application
    Filed: March 11, 2003
    Publication date: November 6, 2003
    Inventors: Kimberly O. Cameron, Bruce A. Lefker, Delvin R. Knight
  • Isothiazole derivatives and their use as pesticides
    Publication number: 20030207926
    Abstract: A compound of formula (I), where A is optionally substituted alkylene, alkenylene, alkynylene, cycloalkylene, alkylenoxy, oxy(C1-6)alkylene, alkylenethio, thio(C1-6)alkylene, C1-6alkylenamino, amino(C1-6)alkylene, [C1-6alkyleneoxy(C1-6)alkylene], [C1-6alkylenethio(c1-6)alkylene], [1-6alkylenesulfinyl(c1-6)alkylene], [c1-6alkylenesulfonyl(C1-6)alkylenc] or [C1-6alkyleneamino(C1-6)alkylene]; provided that A is not CH2 or CH2O; B is N, N-oxide or CR8; Y is O, S or NR9; Z is O, S or NR10; and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 are specified radicals; compositions containing them; processes for making them; and their use as insecticides or fungicides.
    Type: Application
    Filed: November 7, 2002
    Publication date: November 6, 2003
    Inventors: Sarag Armstrong, Nigel John Barnes, Susan Patricia Barnett, Eric Daniel Clarke, Patrick Jelf Crowley, Torquil Eoghan Macleod Fraser, David John Hughes, Christopher John Mathews, Roger Salmon, Stephen Christopher Smith, Russell Viner, William Guy Whittingham, John Williams, Alan John Whittle, William Roderick Mound, Christopher John Urch, Brian Leslie Pilkington, Joan Pilkington
  • Phenyl benzisoxazoles as estrogenic agents
    Publication number: 20030207927
    Abstract: This invention provides estrogen receptor modulators of formula I, having the structure 1
    Type: Application
    Filed: December 11, 2002
    Publication date: November 6, 2003
    Applicant: Wyeth
    Inventors: Michael S. Malamas, Tam Q. Dinh, Iwan Gunawan, Michael D. Collini, Heather A. Harris, James C. Keith, Leo M. Albert
  • Streptogramin derivatives, their preparation and compositions which contain them
    Publication number: 20030207928
    Abstract: Group A streptogramin derivatives of formula (I) and salts thereof: 1
    Type: Application
    Filed: June 10, 2003
    Publication date: November 6, 2003
    Applicant: Aventis Pharma S.A.
    Inventors: Pascal Desmazeau, Baptiste Ronan, Eric Bacque, Jean-Claude Barriere
  • 3-nitroisoxazoles and their use in the protection of materials
    Publication number: 20030207929
    Abstract: The 3-nitroisoxazoles of the formula (I) 1
    Type: Application
    Filed: April 10, 2003
    Publication date: November 6, 2003
    Inventors: Hermann Uhr, Oliver Kretschik, Martin Kugler, Peter Wachtler
  • Valsartan salts
    Publication number: 20030207930
    Abstract: The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.
    Type: Application
    Filed: February 24, 2003
    Publication date: November 6, 2003
    Inventors: Erwin Marti, Hans Rudolf Oswald, Peter Buhlmayer, Wolfgang Marterer
  • USE OF 3-(2-ETHYLPHENYL)-5-(3-METHOXYPHENYL)-1H-1,2,4-TRIAZOLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20030207931
    Abstract: The present invention discloses a method for treating a subject affected by an autoimmune disease, in particular multiple sclerosis, lupus erythematosus systemicus and reumatoid arthritis, comprising administering to said subject an effective amount of 3-(2-ethylphenyl)5-methoxy-1H-1,2,4-triazole. The present invention further discloses a method for inhibiting &ggr;&dgr; T cells in a subject in need thereof, said method comprsing administering to said subject an effective amount of the same compound.
    Type: Application
    Filed: May 3, 2002
    Publication date: November 6, 2003
    Inventors: Luca Battistini, Giovanna Borsellino, Rita De Santis, Paolo Carminati
  • Compositions that prevent post-traumatic hyperpigmentation and methods related thereto
    Publication number: 20030207932
    Abstract: The ingestion or topical administration of substances that inhibit leukotrienes prior to a trauma to the skin and for a period of time thereafter effectively inhibits the development of hyperpigmentation in people so predisposed.
    Type: Application
    Filed: May 1, 2003
    Publication date: November 6, 2003
    Inventor: Morris Mann
  • Compositions and methods for increasing the sensitivity of apoptosis-resistant tumor cells to inducers of apoptosis
    Publication number: 20030207933
    Abstract: Disclosed herein are novel compositions and methods for the treatment of cancer and other diseases. More particularly, the present invention provides compositions and methods for reversing the resistance and increasing the sensitivity of apoptosis-resistant cells to all forms of cancer therapies, such as radiation and chemotherapy, for the treatment of apoptosis-resistant cancers.
    Type: Application
    Filed: January 27, 2003
    Publication date: November 6, 2003
    Inventors: Yuqiang Wang, Susan C. Wright, James W. Larrick
  • Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease
    Publication number: 20030207934
    Abstract: Acylated &agr;-hydroxyarylbutanamines and related sulfonamides, ureas and carbamates that inhibit aspartyl protease are disclosed, as are methods of treating diseases, particularly HIV, using these compounds.
    Type: Application
    Filed: October 22, 2001
    Publication date: November 6, 2003
    Inventors: Yat Sun Or, Guoqiang Wang, John Rougas, Jude Elizabeth Mathews, Kate Ryan Muldoon, Vincent Alfred Boyd, Jens Werner Eckstein, Steven Wayne Riesinger
  • Novel optically active clausenamides, process of the preparation thereof, pharmaceutical composition containing the same and their medical use
    Publication number: 20030207935
    Abstract: The present invention relates to some new optically active clausenamide derivatives, process of the preparation thereof, a pharmaceutical composition containing the same and their medical use, particularly their use in the respects of hypoxia protective, nootropic and neurodegenerative disease such as cerebral ischemia, Alzheimer disease and vascular dementia.
    Type: Application
    Filed: March 26, 2002
    Publication date: November 6, 2003
    Applicant: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Juntian Zhang, Liang Huang, Kemei Wu, Shiming Chen
  • Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
    Publication number: 20030207936
    Abstract: The invention concerns paclitaxel solubilizers and formulations thereof with a high propensity to dissolve paclitaxel. The formulations of the invention reduce or obviate the need for the disadvantageous excipient Cremophor® EL. The formulations of the invention are useful for administering paclitaxel, its derivatives, or pharmaceutically acceptable salts or such derivatives to patients in need thereof. The formulations of the invention are suitable for parenteral, oral, local, or transdermal administration to mammals including humans, particularly for intravenous delivery.
    Type: Application
    Filed: February 3, 2003
    Publication date: November 6, 2003
    Inventor: Hongming Chen
  • 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity
    Publication number: 20030207937
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: March 14, 2003
    Publication date: November 6, 2003
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok-Yin Tsang, Yang-Dar Yuan, Roshantha A. Chandraratna
  • Benzhydryl derivatives
    Publication number: 20030207938
    Abstract: Benzhydryl derivatives of the formula I, 1
    Type: Application
    Filed: October 29, 2002
    Publication date: November 6, 2003
    Inventors: Ingo Rose, Jordi Tormo i Blasco, Markus Gewehr, Wassilios Grammenos, Bernd Muller, Joachim Rheinheimer, Peter Schafer, Frank Schieweck, Thomas Grote, Andreas Gypser, Eberhard Ammermann, Gisela Lorenz, Reinhard Stierl, Siegfried Strathmann, Paul Carter, Jurgen Curtze
  • Novel 3-substituted urea derivatives and medicinal use thereof
    Publication number: 20030207939
    Abstract: The present invention relates to a urea derivative of the formula (1) 1
    Type: Application
    Filed: February 5, 2003
    Publication date: November 6, 2003
    Inventors: Seigo Ishibuchi, Hiroshi Sumichika, Katsuhiko Itoh, Yoichi Naka
  • HYPERICIN AND HYPERICUM EXTRACT: SPECIFIC T-TYPE CALCIUM CHANNEL BLOCKER, AND THEIR USE AS T-TYPE CALCIUM CHANNEL TARGETED THERAPEUTICS
    Publication number: 20030207940
    Abstract: Hypericin has been shown to specifically inhibited T-type calcium channel activity. Hypericum extract containing hypericin also inhibited T-type calcium channel activity. Moreover, other chemicals in Hypericum extract showed a synergistic effect to hypericin. In view of this, hypericin or hypericin-containing Hypericum extract can be used as T-channel blockers. Hypericum extract, extract of other species of the Hypericum genus, extract of other plants containing hypericin, hypericin, hypericin derivatives, hypericin analogs, such as pseudohypericin, and other hypericum extract constituents can be used as therapeutics targeted at T-type calcium channels for treatment of diseases associated with T-channel abnormality. Methods for administering hypericin and hypericum extract are disclosed.
    Type: Application
    Filed: January 11, 2000
    Publication date: November 6, 2003
    Inventors: JACQUELINE J. SHAN, XI-CHEN WU, PETER K. T. PANG, LEI LING
  • Method of treating vascular endothelial growth factor mediated vascular disorders
    Publication number: 20030207941
    Abstract: The use of amfenac and derivatives, including nepafenac, to treat vascular endothelial growth factor mediated vascular disorders.
    Type: Application
    Filed: April 16, 2003
    Publication date: November 6, 2003
    Inventors: David P. Bingaman, Michael A. Kapin, Daniel A. Gamache, Gustav Graff, John M. Yanni